Why Retail Investors Are Eyeing Tyson Foods And Other Defensive Stocks Now

With July inflation data expected to show a small CPI rebound and mixed signals on future Fed moves, many investors are quietly rethinking where they want to sit on the risk spectrum. Defensive sectors like healthcare and consumer staples often come back into focus when inflation and rates feel uncertain. This article walks through three large cap stocks exposed to these inflation trends and explains why some investors are watching them closely now.

The three stocks highlighted below are only a starting sample from this defensive theme, and the full screen surfaced 4 additional large cap healthcare and consumer staples companies with equally compelling stories that are not covered here. To see the complete Defensive Sectors list, analyze your shortlist, and identify which ideas feel most resilient for your portfolio, head straight into the Defensive Sectors (Healthcare & Consumer Staples) screener.

Overview: Tyson Foods is a global food company that turns beef, pork, chicken and other proteins into branded, ready-to-cook and ready-to-eat products sold to supermarkets, restaurants, food service operators and other customers worldwide.

Operations: Tyson Foods generates most of its revenue from Chicken at about US$17.2b, Beef at about US$21.9b and Prepared Foods at about US$10.3b, with smaller contributions from Pork at about US$6.2b and International operations at about US$2.3b.

Market Cap: US$20.4b

Tyson Foods sits at the heart of consumer staples, supplying everyday protein products that tend to hold up when inflation and rates feel uncertain. Yet the story today is far from plain. Chicken and Prepared Foods are pulling their weight, while the Beef segment is under pressure from tight cattle supply and management has cut its 2026 profit outlook and guided to a sizeable Beef operating loss. At the same time, Tyson offers a 3.57% dividend yield, a long list of well known brands and analyst expectations for faster earnings growth than the broader US market. With a CEO transition coming in October 2026 and mixed recent share performance, the balance between opportunity and risk here is more nuanced than a simple defensive label suggests.

Tyson Foods looks like a classic defensive stock, yet its Beef headwinds and profit reset mean the full story is more complex. Get the context behind that mix of resilience and uncertainty in the analysis report for Tyson Foods

Build your own resilient dividend and defensives shortlist

Tyson Foods and the two other stocks in this article all surfaced from a single screen, but the real value comes from tailoring the filters yourself. Use our flexible Screener to combine metrics like valuation, dividends, balance sheet strength and risks, or jump straight into our curated Investing Ideas for ready made themes to explore.

Overview: U.S. Physical Therapy runs a large network of outpatient physical therapy clinics across the U.S., treating everything from post-surgery rehab and sports injuries to work related and neurological conditions. It also provides on site injury prevention, testing and ergonomic services for large employers and insurers through a separate industrial injury prevention arm.

Market Cap: US$1.2b

Investors looking at healthcare defensives may find U.S. Physical Therapy interesting because it ties steady demand for musculoskeletal care to growing employer focused health services. Recent results show record visit volumes and rising revenue, supported by new hospital alliances such as the NYU Langone affiliation, even as margins remain under pressure from higher labor and benefit costs. The company sits at a crossroads where Medicare reimbursement, wage trends and digital competition all matter, yet analysts still see room for earnings to improve from today’s thin 0.3% net margin. With July CPI keeping healthcare inflation in focus and management raising EBITDA guidance for 2025, the bigger question is how much of that potential is already priced into the stock and what could shift the story next.

U.S. Physical Therapy is seeing record visit volumes and higher revenue, yet earnings are still thin and labor costs are biting. Get the full picture in the analysis report for U.S. Physical Therapy

Overview: Humana is a large U.S. health insurer focused on Medicare Advantage and related prescription drug, dental, vision and supplemental plans, alongside its CenterWell primary care, home health and pharmacy services for seniors. The company combines insurance products with care delivery to manage health outcomes and costs for millions of older Americans and military members.

Operations: Humana generates around US$139.7b in revenue from its Insurance segment and about US$24.7b from CenterWell, with internal eliminations of roughly US$18.8b, and all of its US$145.8b revenue comes from the United States.

Market Cap: US$46.2b

Humana gives you exposure to healthcare, which tends to hold up when inflation is sticky and rates stay in focus. However, the story is more nuanced than a simple defensive label. The company is focusing on Medicare Advantage profitability, value based primary care through CenterWell and AI driven efficiency, while also managing thinner margins, one off losses and evolving Star ratings and reimbursement rules. Analysts and recent Q2 updates point to potential margin recovery by 2028, but earnings have compressed and funding is fully reliant on external borrowing. For investors considering a large insurer exposed to ongoing healthcare demand and meaningful regulatory and cost risks, Humana may warrant further research.

Humana’s margin recovery story is tied to Medicare Advantage, CenterWell and AI efficiency, yet thin margins and funding needs sit in the background. See how analysts frame that trade off in the analyst forecasts for Humana

Seeking Fresh Alternatives Before Others Do

Fresh stock ideas do not stay quiet for long. Spot breakouts, early momentum and stocks still flying under the radar for now. Information ages quickly, so get in early.

• Catch early price and earnings momentum across companies that screen as high quality and potentially mispriced through the 52 high quality undervalued stocks before the crowd turns its attention their way.
• Track where serious income seekers may be heading next by reviewing a curated set of high yield opportunities using the 8 dividend fortresses while payouts and fundamentals still align.
• Follow capital as it shifts toward companies with stronger finances by scanning a focused list of solid balance sheet and fundamentals (48 results) and avoid getting caught holding weaker balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com